Recently, sirolimus, a drug that targets the mammalian target of rapamycin (mTOR) downstream of the VEGF pathway, was effective in regressing tumor mass in a patient with segmental IH who had been unresponsive to treatment [25]. The gene discussed is VEGFA; the disease is neoplasm.